



**HAL**  
open science

# Alcam-a and Pdgfr- $\alpha$ are essential for the development of sclerotome derived stromal cells that support hematopoiesis in vivo.

Emi Murayama, Catherine Vivier, Anne Schmidt, Anne-Lou Touret, Philippe Herbomel

## ► To cite this version:

Emi Murayama, Catherine Vivier, Anne Schmidt, Anne-Lou Touret, Philippe Herbomel. Alcam-a and Pdgfr- $\alpha$  are essential for the development of sclerotome derived stromal cells that support hematopoiesis in vivo.. 2022. hal-04233146v1

**HAL Id: hal-04233146**

**<https://hal.science/hal-04233146v1>**

Preprint submitted on 29 Aug 2022 (v1), last revised 16 Oct 2023 (v2)

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

# Alcam-a and Pdgfr- $\alpha$ are essential for the development of sclerotome derived stromal cells that support hematopoiesis in vivo.

Emi Murayama (✉ [emur@pasteur.fr](mailto:emur@pasteur.fr))

Institut Pasteur <https://orcid.org/0000-0002-5311-1594>

Catherine Vivier

Institut Pasteur

Anne Schmidt

Institut Pasteur

Anne-Lou Touret

Institut Pasteur

Philippe Herbomel

Institut Pasteur <https://orcid.org/0000-0002-8946-3313>

---

## Article

### Keywords:

**Posted Date:** March 2nd, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1401814/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

**Title:** Alcam-a and Pdgfr- $\alpha$  are essential for the development of sclerotome derived stromal cells that support hematopoiesis in vivo.

**Authors:** Emi Murayama<sup>\*,1,2,3</sup>, Catherine Vivier<sup>1,3</sup>, Anne Schmidt<sup>1,3</sup>, Anne-Lou Touret<sup>1,3,4</sup>, and Philippe Herbomel<sup>1,3</sup>

<sup>1</sup> Institut Pasteur, Department of Developmental & Stem Cell Biology, Paris 75015, France.

<sup>2</sup> INSERM, Paris 75013, France.

<sup>3</sup> CNRS, UMR3738, Paris 75015, France.

<sup>4</sup> Sorbonne Université, Ecole doctorale Complexité du Vivant, Paris 75005, France.

\* Author for correspondence ([emur@pasteur.fr](mailto:emur@pasteur.fr))

1 **Abstract**

2       Mesenchymal stromal cells are essential components of hematopoietic stem  
3 and progenitor cell (HSPC) niches, regulating HSPC proliferation and fate decisions.  
4 Their developmental origins are largely unknown. In zebrafish, we previously found  
5 that the stromal cells of the caudal hematopoietic tissue (CHT), a niche functionally  
6 homologous to the fetal liver in mammals, arise from the ventral part of caudal somites.  
7 We have now discovered that this ventral domain is actually the sclerotome, and that  
8 two typical markers of mammalian mesenchymal stem/stromal cells, Alcam and Pdgfr-  
9  $\alpha$ , are distinctively expressed there and instrumental for the emergence and migration  
10 of stromal cell progenitors, which in turn conditions the proper assembly of the vascular  
11 component of the CHT niche. Furthermore, we find that the trunk somites are similarly  
12 dependent on Alcam and Pdgfr- $\alpha$  to produce mesenchymal stromal cells that foster  
13 the initial emergence of HSPCs from the dorsal aorta. Thus the sclerotome contributes  
14 essential stromal cells for each of the key steps of developmental hematopoiesis, and  
15 likely is the embryological origin of most if not all mesenchymal stem/stromal cells  
16 found in non-cephalic tissues.

17  
18  
19

## 1 **Introduction**

2 Hematopoietic stem and progenitor cells (HSPCs) are multipotent precursors  
3 that have self-renewal capacity and continuously replenish all mature blood cells  
4 throughout the life span. In zebrafish as in mammalian development, they initially  
5 emerge from the dorsal aorta of the embryo through an endothelial hematopoietic  
6 transition (EHT)<sup>1,2,3,4</sup>. Then they enter the bloodstream to reach their first niche, the  
7 caudal hematopoietic tissue (CHT)<sup>5</sup>, where they expand and undergo their first multi-  
8 lineage differentiation<sup>6</sup>. Thus the CHT in fish is the hematopoietic homolog of the fetal  
9 liver in mammals. In our previous work, we showed that the CHT niche was mainly  
10 composed of a transient venous plexus arisen from the primitive caudal vein, and  
11 stromal reticular cells (SRCs) interconnecting as well as lining the branches of this  
12 venous plexus<sup>5,7</sup>.

13 We then discovered that the progenitors of these stromal cells initially arose  
14 from the ventral part of the caudal somites through an epithelial mesenchymal  
15 transition (EMT)<sup>7</sup>. These stromal cell progenitors (SCPs) then emigrated as strings of  
16 2-3 cells further ventrally, in close interaction with the endothelial cells sprouting from  
17 the primitive caudal vein that would make up the venous plexus<sup>7</sup>. This early interaction  
18 of the precursors of the two cell types that would constitute the CHT niche was  
19 presumably important for the very structure and functionality of that niche. In the  
20 present study we have more closely characterized the process of SCP emergence and  
21 emigration from the caudal somites and identified important molecular actors in this  
22 process. Moreover, since the sclerotome compartment of the somites lies at their  
23 ventro-medial side, and undergoes EMT and subsequent emigration to produce the  
24 various sclerotome derivatives<sup>8,9</sup>, we have addressed its relationship with the ventral  
25 cell clusters of the caudal somites that give rise to the SCPs.

26 Activated leukocyte cell adhesion molecule (Alcam or CD166) is a large cell  
27 surface glycoprotein of the immunoglobulin superfamily that mediates adhesion  
28 through homophilic interactions in various tissues<sup>10</sup>, and heterophilic interactions with  
29 CD6 at the interface of T cells and antigen-presenting cells<sup>11</sup>, and with galectin-8 in the  
30 extracellular matrix<sup>12</sup>. While expressed in a wide variety of tissues, Alcam is often found  
31 in cell subsets involved in dynamic growth and/or migration processes including neural  
32 development<sup>13</sup>, pharyngeal pouch formation<sup>14</sup>, angiogenesis<sup>15</sup>, kidney development<sup>16</sup>  
33 hematopoiesis<sup>17</sup>, and tumor progression<sup>18</sup>; it is also found in mesenchymal stem cells  
34 (MSCs) / bone marrow and fetal liver stromal cells<sup>19,20,21</sup>. The short cytoplasmic tail of

1 Alcam was shown to interact indirectly with the actin cytoskeleton via actin-binding  
2 proteins such as ezrin and syntenin-1<sup>22</sup>. These interactions of the cytoplasmic domain  
3 dynamically regulate the clustering of Alcam molecules at the cell surface and the  
4 strength of the homophilic and heterophilic interactions<sup>23,24</sup>.

5 Platelet-derived growth factor receptor  $\alpha$  (PDGFR- $\alpha$ ) is a highly conserved  
6 receptor tyrosine kinase. Binding of PDGFs to PDGF receptors induces their  
7 dimerization, which unlocks their tyrosine kinase activity and results in  
8 autophosphorylation of specific tyrosine residues, which then act as binding sites for  
9 intracellular Src homology 2 (SH2) domain-containing signaling molecules<sup>25,26</sup>.  
10 PDGFR- $\alpha$  mediated signaling regulates various processes of embryonic development  
11 and organogenesis, notably the proliferation then migration and differentiation of  
12 specialized mesenchymal cells in various organ anlagen<sup>27</sup>. Like Alcam, PDGFR- $\alpha$  is  
13 also a marker of bone marrow MSCs<sup>19,28</sup>.

14 Here we identify Alcama and Pdgfr- $\alpha$  as two essential transmembrane proteins  
15 in the process of SCP emergence from somite epithelial cells, their subsequent  
16 migration to become stromal cells, and for the resulting structure and functionality of  
17 the CHT niche. We further show that the somite ventral clusters giving rise to them  
18 coincide with the caudal sclerotome, and that Alcama and Pdgfra are similarly  
19 important for the emergence from the trunk somites of sub-aortic mesenchymal cells  
20 that are essential for the induction of HSPCs from the aorta.

## 1 Results

2

### 3 **Alcama is required for stromal cell development from the somites**

4 We previously described that cell clusters containing SCPs appeared at the  
5 ventral side of caudal somites by 21-22 hpf<sup>7</sup>. Somite formation occurs in rostro-caudal  
6 direction and we found that the SCP clusters first become apparent by live VE-DIC  
7 microscopy in the transition from somite maturation stage S4 to S5 (4th and 5th somite  
8 from the tailbud)<sup>29</sup> (Fig. 1A). During cluster formation, the cells located on the ventral  
9 side of the somites adopt a rosette-like structure with a small cavity in the center (Fig.  
10 1A-a; Movie 1). To visualize the subsequent emigration of SCPs from these ventral  
11 clusters (VCs), we previously used TCF-driven fluorescent reporters expressed in all  
12 somite cells, which were merely inherited by the emigrating SCPs<sup>7</sup>. To analyze the fate  
13 of these SCPs, we first used the *Tg(pax3a:eGFP)* and *Tg(ET37:eGFP)* lines<sup>30</sup>.  
14 *Tg(pax3a:eGFP)* labelled somite cells weakly, then the VCs more strongly, as well as  
15 the migrating SCPs up to 2.5 dpf (Movie 2). The *Tg(ET37:eGFP)* line also highlights  
16 somite cells weakly<sup>30</sup>, but then starts to label SCPs more strongly from the onset of  
17 their emigration from the somites (Fig. S1A). While these two lines proved useful for  
18 our study, we also set out to create a new Tg line that would label the SCPs more  
19 specifically and throughout their development. We firstly searched for genes that  
20 seemed specifically expressed in the VCs in the ZFIN whole-mount in situ hybridization  
21 (WISH) databank. Our subsequent confirmation by WISH of candidate genes between  
22 23-48 hpf led us to target the chondroitin sulfate proteoglycan 4 (*cspg4*) gene (Fig.  
23 S1B). We then generated a BAC-based Tg line expressing the GAL4 transcription  
24 factor (TF) from the *cspg4* regulatory regions. This *TgBAC(cspg4:GAL4)* line crossed  
25 with a *Tg(UAS:RFP)* reporter line faithfully recapitulates the *cspg4* gene expression  
26 pattern spatiotemporally (Figs. 1B, S1C). With the exception of the notochord, RFP  
27 expression highlights only the VCs and their derivatives in *Tg(cspg4:GAL4;UAS:RFP)*  
28 embryos. By 29 hpf, the GFP signal from *Tg(ET37:eGFP)* was also clearly visible and  
29 the migration of RFP<sup>+</sup>GFP<sup>+</sup> cells was observed towards not only the ventral but also  
30 the dorsal side (Fig. S1C). The latter cell population migrated along the medial face of  
31 the somites towards the notochord (Fig. S1D), suggesting chondro-progenitor and/or  
32 tenocyte fates<sup>8,9,31</sup>. Ventral-wards migrating SCPs gave rise to stromal cells throughout  
33 the CHT by 38 hpf, and some migrated even further ventrally to become fin

1 mesenchymal cells<sup>30</sup> (FMCs) in the caudal fin (Fig. 1B-b). These three fates of somite  
2 VC derived cells are recapitulated in Fig. S1D.

3 To understand how somite epithelial cells compartmentalize to give rise to the  
4 VCs and their derivatives, we also searched for cell adhesion molecules expressed  
5 specifically in the VCs. We found that *alcama* (activated leukocyte cell adhesion  
6 molecule a, aka CD166), was expressed in the VCs more strongly than in the bulk of  
7 the somites at 23 hpf (Fig. 1C). Immunofluorescence allowed us to detect the Alcama  
8 protein at the very core of the clusters as they first appeared morphologically, i.e. at  
9 somite stage S5 (Fig. 1D-a,b). Upon somite maturation, Alcama protein signals then  
10 gradually propagated to delineate cell boundaries within the clusters (Fig. 1D-a,b). We  
11 then detected the Alcama protein at joints between cluster-derived cells migrating both  
12 ventral- and dorsal-wards (Fig. 1D-c). We first examined the impact of *alcama* knock-  
13 down by using an antisense morpholino oligonucleotide (MO), that completely blocked  
14 translation of the *alcama* transcript in vivo (Fig. S1E,F). Injection in  
15 *Tg(pax3a:eGFP;TCF:nls-mCherry)* embryos revealed that while in control embryos,  
16 SCPs initially migrated as strings of 2-3 cells interconnected by a rather large contact  
17 surface (Fig. 1E-a,c), which immunostaining showed to be enriched in Alcama protein  
18 (Fig. 1D-c), in *alcama* morphants, adhesion between migrating SCPs was reduced to  
19 a very small surface at the tip of an elongated cell protrusion (Fig. 1E-b,d). We next  
20 crossed our *TgBAC(cspg4:GAL4;UAS:RFP)* line with *Tg(UAS:Lifeact-eGFP)*<sup>32</sup>, in  
21 which Lifeact-eGFP allows to highlight F-actin in vivo, so as to visualize actin dynamics  
22 and cellular projections during SCP emergence and migration. Lifeact-eGFP<sup>+</sup> VC-  
23 derived cells were clearly less numerous in *alcama* morphants by 26 hpf (Fig. 1F) - a  
24 finding confirmed in the *Tg(ET37:eGFP)* background (Fig. 1G). This reduced number  
25 was later mirrored by a similarly (2.7-fold) lower number of SCPs after migration into  
26 the CHT by 30 hpf (Fig. 1G), and a clearly lower number of both stromal cells in the  
27 CHT and FMCs by 46 hpf (Fig. 1H).

28

### 29 **Alcama regulates the migration behavior of SCPs by modulating F-actin**

30 Time-lapse imaging of migrating Lifeact-GFP<sup>+</sup> SCPs in *alcama* morphants  
31 revealed a characteristic cell morphology compared to SCPs in control embryos (Fig.  
32 2A). Filopodial projections in migrating leader SCPs usually occur mainly at the leading  
33 edge, whereas they were 50% more numerous (Fig. S2A-a) and more randomly  
34 scattered around the migrating cell in *alcama* morphants (Fig. 2B). In addition, even



1 though they were slightly longer on average in *alcama* morphants (Fig. S2A-b), unlike  
2 in control embryos their length did not correlate with their position relative to the  
3 direction of migration (Fig. 2C). A further quantitative analysis of confocal live images  
4 showed that i) a high Lifeact-GFP (F-actin) signal was present throughout migrating  
5 SCPs in *alcama* morphants whereas the F-actin signal was observed predominantly  
6 at the leading edge in controls (Fig. S2B), and (ii) the surface area of migrating SCPs  
7 in *alcama* morphants was much larger than in controls (Fig. S2C). These changes in  
8 morphology and F-actin distribution correlated with a strong defect in SCP migration,  
9 as their linear distance of migration in *alcama* morphants was less than half that in the  
10 control group (Fig. 2D). Later on, by 46 hpf, this migration defect had translated in a  
11 much thinner distribution of ET37:GFP<sup>+</sup> stromal cells in the CHT (Fig. 1H).

12 To gain more insight into the implication of *Alcama* in SCP migration, we took  
13 advantage of *Tg(cspg4:Gal4)* driver line to express specifically in these cells three  
14 different forms of *Alcama* fused to eGFP at its C-terminus – a WT full-length *Alcama*  
15 (*Alcama-FL-eGFP*), and two mutant forms, i) *Alcama-ΔN-eGFP*, lacking both N-  
16 terminal Ig-like V-type domains that are known to mediate homophilic cell adhesion<sup>33</sup>,  
17 and ii) *Alcama-ΔPDZ-eGFP*, in which we introduced in the short cytoplasmic domain  
18 of *Alcama* three amino acid changes predicted to suppress the binding of PDZ domain  
19 containing proteins (Fig. S2D), such as *syntenin*<sup>22</sup>. These different forms were inserted  
20 downstream of a UAS promoter, and the constructs were injected in  
21 *Tg(cspg4:Gal4;UAS:RFP)* embryos. Expression of *Alcama-FL-eGFP* in the VCs did  
22 not perturb SCP emergence and migration (Fig. S2E, Movie 3). In contrast, SCPs  
23 expressing *Alcama-ΔN-eGFP* appeared disconnected from their neighbors within the  
24 VCs, and soon developed an intense filopodial dynamics while still within the somite  
25 (Fig. 2Ea-c, Movie 4), but most often with no resulting ventral-wards migration towards  
26 the CHT, whereas internal control neighboring RFP<sup>+</sup>GFP<sup>-</sup> cells migrated normally (Fig.  
27 2E-d). *Alcama-ΔPDZ-eGFP*<sup>+</sup> VC cells and their SCP derivatives displayed much less  
28 filopodia compared to WT or *Alcama-ΔN-eGFP* expressing cells; they still showed  
29 some GFP enrichment at cell-cell contacts, but no clear polarity (Fig. 2Fa-c, Movie 5).  
30 Like *Alcama-ΔN-eGFP* expressing cells, *Alcama-ΔPDZ-eGFP*<sup>+</sup> SCPs barely migrated  
31 to the ventral side, compared with (RFP<sup>+</sup>GFP<sup>-</sup>) SCPs in the same embryo (Fig. 2F-d).  
32 However, the dorsal-wards migration was rather retained for GFP<sup>+</sup> cells in both cases,  
33 as well as for *Alcama-FL-eGFP* expressing cells (Figs. 2G, S2F,G). In vivo tracking of  
34 GFP<sup>+</sup> cells in both *Alcama-ΔN-eGFP* and *-ΔPDZ-eGFP* expressing embryos confirmed

1 that the cells that egressed ventrally from the clusters then wandered around and  
2 migrated only shortly towards the ventral side, whereas the dorsal-wards migration  
3 was similar to that of wild-type SCPs or Alcama-FL-eGFP expressing cells (Fig. 2H,I).  
4 Statistical analysis of their fates confirmed that the phenotype of GFP<sup>+</sup> mutant cells  
5 was predominantly 'immobile' or 'dorsal migration', with occasional 'ventral migration'  
6 limited to a short distance (Fig. 2J). Altogether, these data show that Alcama is cell-  
7 autonomously involved in SCP emergence and migration.

8

### 9 **Alcama and PDGFR- $\alpha$ deficiency similarly affect SCP development**

10 A prominent feature of *alcama* morphant and dominant-negative mutant  
11 phenotypes was the inhibition of SCP ventral migration. Therefore, we investigated the  
12 gene expression of receptors for cytokines and growth factors that might be involved  
13 in SCP migration. We found that *pdgfr- $\alpha$* , a bone marrow stromal cell marker gene in  
14 mammals<sup>28</sup>, was specifically expressed in the somite VCs, starting by somite  
15 maturation stage S6, and then in the migrating cells derived from them (Fig. 3F-a,c).  
16 Therefore we hypothesized a possible cross-talk between Alcama and Pdgfr- $\alpha$ . It is  
17 known that PDGF signaling leads to an increase in AKT and ERK phosphorylation<sup>34,35</sup>.  
18 We firstly investigated the impact of *alcama* knock-down on pERK signaling in the  
19 caudal region at 26 hpf. The number of pERK<sup>+</sup> cells was drastically decreased in the  
20 CHT of *alcama* morphants, while it recovered to almost the control level in the rescued  
21 group (Fig. 3A). Then, we analyzed the impact of Pdgfr- $\alpha$  deficiency, using a previously  
22 validated MO against *pdgfra*<sup>36</sup>. First, we analyzed the colocalization of pERK-positive  
23 cells with SCPs marked by *pax3a*-GFP in *alcama* and *pdgfra* morphants. While in  
24 control embryos we could observe pERK<sup>+</sup>GFP<sup>+</sup> migrating SCPs, in *alcama* and *pdgfra*  
25 morphants the overall number of pERK<sup>+</sup> cells was reduced, and no pERK signal was  
26 observed among migrating SCPs (Fig. S3A).

27 Time-lapse imaging of SCP emergence in *pdgfra* morphants by 23-24 hpf  
28 revealed that the cohesion of the VCs was compromised, with groups of cells often  
29 delaminating together from the somite (Fig. S3B), and then several SCPs per somite  
30 cluster or cell group starting to emigrate simultaneously (Fig. 3B), yet with a clearly  
31 reduced migration efficiency relative to WT. Quantification showed that the numbers  
32 of CHT stromal cells and FMCs originating from SCPs were reduced 2.4-fold and 2.0-  
33 fold, respectively, in *pdgfra* morphants by 40 hpf (Fig. 3C), similar to what we  
34 previously found for *alcama* morphants (Fig. 1H). Live imaging also showed that like

1 in *alcama* morphants, the extent of ventral-wards migration of SCPs by that time was  
2 much reduced in the *pdgfra* morphants (Movie 6), and this apparently directly impacted  
3 on the co-migration of endothelial cells that made the venous plexus, resulting in a  
4 much thinner venous plexus, often reduced to a single convoluted tube, in tight  
5 apposition to the overlying caudal artery, which could locally show a reduced diameter  
6 (Fig. 3D). We then attempted to identify PDGF ligands that would activate *Pdgfr- $\alpha$*   
7 signaling in the VCs and migrating SCPs. pERK immunostaining was performed on  
8 embryos overexpressing either of three different PDGFs whose ventro-caudal specific  
9 expression had been confirmed by WISH (Fig. S3C). All three ligands were found to  
10 activate pERK signaling, hence likely *Pdgfr- $\alpha$*  signaling; however the effect of *Pdgfaa*  
11 was statistically most significant (Fig. S3D).

12

### 13 **PDGFR- $\alpha$ drives SCP migration through PI3K signaling**

14 PI3K signaling is known to be activated downstream of various growth factor  
15 receptors including PDGF receptors<sup>37</sup> following their activation. Pharmacological  
16 inhibition of PI3K isoforms using AS605240 (inhibiting PI3K isoforms  $\gamma$ ,  $\alpha$ ), LY294002  
17 (inhibiting isoforms  $\alpha$ ,  $\beta$ ,  $\delta$ ) or CAL101 (inhibiting isoform  $\delta$ ) revealed that the migration  
18 of SCPs was compromised in embryos treated with LY294002, and more so with  
19 AS605240, resulting in a 3.5-fold reduction in stromal cell numbers by 40 hpf (Fig. 3E),  
20 whereas *pax3a-GFP<sup>high</sup>* neural crest cells migrated with only a slight delay (Fig. S3E,  
21 blue arrows). To monitor SCP migration over longer intervals, AS-treated embryos  
22 were fixed and labeled with a *pdgfra* in situ probe at stages encompassing the entire  
23 SCP migration process. In the control group, dorsal-wards migration of VCs derived  
24 cells had already started by 23 hpf, whereas no migration was observed in the AS-  
25 treated embryos (Fig. 3F-a,c). By 36 hpf, SCP migration had not started yet in the AS-  
26 treated group, in which SCPs accumulated at the zone of their emergence, while it was  
27 already complete in the control group (Fig. 3F-b,d).

28 Since the involvement of PI3K in SCP migration was revealed, we then mutated  
29 two tyrosine residues in the intracellular domain of *Pdgfr- $\alpha$*  that are responsible for the  
30 binding of class IA ( $\alpha$ /  $\beta$ /  $\delta$ ) PI3K to *Pdgfr- $\alpha$*  following its activation and  
31 autophosphorylation<sup>34</sup> (Fig. 4A), and we cloned the mutated or WT *pdgfra* ORF  
32 followed by a tandem HA-tag downstream of a *hsp70* promoter<sup>38</sup> (*hsp70:pdgfra- $\Delta$ PI3K-  
33 HA* or *hsp70:pdgfra<sup>WT</sup>-HA*, respectively). Transient transgenics resulting from injection

1 of the hsp70:pdgfra- $\Delta$ PI3K-HA or hsp70:pdgfra<sup>WT</sup>-HA construct in *Tg(pax3a:GFP)*  
2 embryos were heat-shocked at 20 hpf, then imaged in vivo from 23 hpf, or fixed for  
3 immunofluorescence at the same time point. The anti-HA antibody positive signals  
4 sometimes showed a mosaic distribution, but were sufficiently present in the targeted  
5 tissue of hsp70:pdgfra- $\Delta$ PI3K-HA and hsp70:pdgfra<sup>WT</sup>-HA embryos at 24 hpf (Fig.  
6 S4A). Heat-shocked hsp70:pdgfra- $\Delta$ PI3K-HA embryos typically showed a less clear  
7 outline of the somite VCs than controls. In addition, 38% of them showed multiple SCPs  
8 simultaneously initiating migration from one somite, reflecting the lack of leader cell,  
9 and 20.5% had at least one somite showing an 'overflow' phenotype in which the VC  
10 collectively delaminated into the ventro-caudal cavity, reminiscent of the phenotype  
11 observed above in *pdgfra* morphants; these cell populations tended to disperse over  
12 time, but did not go through the normal migration process (Figs. 4B, S4B). In embryos  
13 overexpressing the *pdgfra*<sup>WT</sup>-HA construct, more apoptotic bodies were detected than  
14 in WT embryos, but no abnormalities were observed in the VCs and emigration of  
15 SCPs (Fig. S4C). Interestingly, the morphology of migrating SCPs in *pdgfra- $\Delta$ PI3K*  
16 expressing embryos was quite similar to that observed in *alcama* morphants, with long  
17 and numerous filopodia and the cell's main axis often orthogonal to the ventral-wards  
18 direction of migration (Fig. 4C, Movie 7), and with increased 3D cell surface area and  
19 volume (Fig. S4D,E). Importantly, the number of VCs derived GFP<sup>+</sup> cells was clearly  
20 more decreased for those migrating ventral-wards (SCPs) than for those migrating  
21 dorsal-wards (DMCs) (Fig. 4D), again as previously observed upon *Alcama* deficiency.  
22 The total number of SCPs at 36 hpf in the CHT of *pdgfra- $\Delta$ PI3K* expressing embryos  
23 was also strongly reduced (Fig. 4E), as in *Alcama*- or *Pdgfra*-deficient embryos.

24

## 25 **Alcama and Pdgfr- $\alpha$ expression are regulated by sclerotomal transcription** 26 **factors**

27 Since our live imaging revealed that the somite VCs giving rise to SCPs also  
28 gave rise to cells migrating dorsal-wards towards the notochord, it suggested an  
29 overlap or identity of SCP clusters with the sclerotome. Our WISH analysis revealed  
30 that TFs considered as sclerotome markers, such as *Pax9*, *Snai2*, *Twist1a* and *Twist1b*  
31 were indeed expressed in the VCs of caudal somites from the S4/S5 somite stage, and  
32 also quite earlier - from the S1 stage - for *Snai2* (Fig. 5A). Therefore, we investigated  
33 if these TFs regulate the expression of *alcama* and *pdgfra* during SCP development.

1 To this end, we first isolated promoter regions of the *alcama* (3.3 kb) and *pdgfra* (3.2  
2 kb) genes from BACs, and cloned them into the pGL3 Basic vector to monitor their  
3 promoter activity in vivo in various conditions through a Dual luciferase assay  
4 performed on tail lysates at 23 hpf (Fig. 5B-a,E-a).

5 Co-injection of the pGL3-*alcama*-luc construct with either *snai2* MO or *pax9*  
6 mRNA attenuated the *alcama* promoter activity, while co-injection with *snai2* mRNA or  
7 *pax9* MO had no significant effect (Fig. 5B-b). Consistent with this, *alcama* mRNA  
8 expression in the tail of *pax9* morphants was upregulated at 24 hpf (Fig. 5C), while it  
9 was down-regulated in the tail of *snai2* morphants (Fig. 5G). We similarly analyzed the  
10 effects of *twist1a/twist1b* and *snai2* on the *pdgfra* promoter by co-injection with pGL3-  
11 *pdgfra*-luc. Double knockdown of *twist1a* and *1b* led to a drastic decrease in *pdgfra*  
12 promoter activity in the tail samples, whereas co-injection of *twist1b* mRNA stimulated  
13 it (Fig. 5E-b). In line with this, *pdgfra* mRNA expression in the tail was downregulated  
14 in *twist1a/1b* morphants (Fig. 5F). *Snai2* MO also reduced the *pdgfra* promoter activity  
15 (Fig. 5E-b), and consistently, *pdgfra* expression in the tail of *snai2* morphants was  
16 significantly reduced (Fig. 5G). Finally, we found that these sclerotomal TFs regulated  
17 each other in the tail, as *pax9* knockdown up-regulated *snai2* expression but down-  
18 regulated *twist1b*, while *snai2* knockdown down-regulated *pax9* (Fig. 5D,G). The  
19 network of genetic interactions deduced from all these data is depicted in Fig. 5H.

20

## 21 **Alcama and Pdgfr- $\alpha$ are also essential for the production of mesenchymal** 22 **derivatives of trunk somites, and of definitive HSPCs**

23 The expression of *Alcama*, *Pdgfra*, and the sclerotomal TFs mentioned above  
24 in the ventral-most part of zebrafish somites is not restricted to the tail, but also extends  
25 to the somites of the trunk (Fig. 6A). Moreover, as in the tail, *pax3a:eGFP<sup>+</sup>* or  
26 *ET37:eGFP<sup>+</sup>* mesenchymal cells are present in the trunk by 36 hpf, notably just lateral  
27 or ventral to the dorsal aorta, in close contact with it or with the dorsal wall of the  
28 underlying axial vein (Fig. 6B,6C-a,6D-a, and Movie 8). As in the caudal region, we  
29 found that *Alcama*, *Pdgfr-a* or *Pax9* deficiency led to a strong reduction of these  
30 *pax3a:GFP<sup>+</sup>* or *ET37:eGFP<sup>+</sup>* stromal cells of the trunk (Fig. 6C,D). In addition, these  
31 cells were found lateral or ventro-lateral to the aorta, but never just ventral to it (Fig.  
32 6C,D). By 52 hpf, the total number of *GFP<sup>+</sup>* stromal cells in the trunk of all morphants  
33 was even more reduced relative to control embryos than at 36 hpf (Fig. S5).

1           36 hpf is the developmental stage by which definitive HSPCs start to emerge by  
2 EHT from the ventral wall of the aorta - a process that peaks by 48-52 hpf. We found  
3 that *Alcama*, *Pdgfr- $\alpha$*  or *Pax9* deficiency all caused a dramatic reduction in *myb*<sup>+</sup>  
4 HSPCs in the trunk by 36 hpf (Fig. 6E,F). At the same time-point, we could observe  
5 the beginning of *myb*<sup>+</sup> HSPC colonization of the CHT of control embryos, whereas  
6 almost no *myb*<sup>+</sup> cell was detected in the CHT of all morphants (Fig. 6E-a). Then, at 52  
7 hpf, only few *myb*<sup>+</sup> HSPCs were found in the trunk of all morphants, even less than at  
8 36 hpf, while *myb*<sup>+</sup> cells were numerous in control embryos, and very few *myb*<sup>+</sup> HSPCs  
9 were detected in the CHT of all morphants (Fig. 6E-b). Thus the severe impact of  
10 *Alcama* or *Pdgfr- $\alpha$*  deficiency on the development of sclerotome-derived stromal cells  
11 both in the trunk and in the tail led to a profoundly defective definitive hematopoiesis.  
12

## 1 **Discussion**

2        Mouse studies have shown the presence of various stromal cell subsets in  
3 hematopoietic stem cell niches<sup>39</sup>. However, the developmental process and behavior  
4 of these cells, and the molecules involved in cell-cell interactions during niche  
5 formation, remain a mystery. In the present study, we have taken advantage of the  
6 accessibility to in vivo observations of the zebrafish CHT, the hematopoietic homolog  
7 of the fetal liver niche in mammals, to provide new insights into the genesis of stromal  
8 cells. We previously found that the stromal cells of the CHT arose from ventral clusters  
9 (VCs) within the caudal somites. We report here a new transgenic line,  
10 *TgBAC(cspg4:GAL4)*, that specifically labels these VCs and their derivatives, notably  
11 the SCPs throughout their development, and at least two other types of mesenchymal  
12 cells - dorsal-wards migrating cells (DMCs) and fin mesenchymal cells (FMCs)<sup>30</sup>.  
13 Considering that the cell population originating from the caudal somites that  
14 differentiates into osteoblasts in adult fish<sup>40</sup> may also be included, cells derived from  
15 the VCs may have the potential of mesenchymal stem cells (MSCs). VC cells  
16 specifically express sclerotome marker genes such as *twist1*, *snai2* or *pax9*, and their  
17 anatomical location also supports their sclerotomal nature. The three transmembrane  
18 molecules that we found here to be more specifically expressed in the VCs and their  
19 derivatives, *Cspg4*, *Alcama* and *Pdgfr- $\alpha$* , have all been used as markers of bone  
20 marrow and/or fetal liver MSCs in mammals<sup>19,28, 39,41</sup>. Our tracing of the SCPs back to  
21 the VCs of the caudal somites allows us to connect the concept of MSCs, which arose  
22 from studies of in vitro cell cultures from postnatal mammals, to the embryological  
23 concept of sclerotome. The VC-derived DMCs would notably give rise to chondrocytes  
24 and tenocytes<sup>8,9,31</sup>. It will be important to study whether the 'commitment' process<sup>42</sup>,  
25 which corresponds to the first branching point in the differentiation of MSCs into various  
26 cell lineages, may already take place within the VCs.

27        It is the outstanding optical clarity of the ventro-caudal region of zebrafish  
28 embryos as the caudal somites develop that allowed us to identify for the first time the  
29 earliest morphological individualization of the sclerotome, as a distinct ventral cell  
30 cluster appearing at somite maturation stage S5, before these cells become  
31 mesenchymal cells migrating both dorsal- and ventral-wards. Interestingly,  
32 Naganathan et al.<sup>43</sup> recently found that up to stage S4, somites undergo a mechanical  
33 adjustment of their A-P length that is facilitated by somite surface tension, which  
34 requires the somite to be fully packed within an uninterrupted basal lamina. It therefore

1 makes sense that cell migrations out of the somite, which require to break the basal  
2 lamina, are “allowed” to begin only once this mechanical rearrangement of the somite  
3 has been completed, i.e. from somite stage S4/S5. Morphological individualization of  
4 VCs by stage S5 appears to closely follow the onset of expression at the same place  
5 of the sclerotomal TF genes as well as *alcama*. It may thus reflect the EMT triggered  
6 by Twist1/Snai2/Pax9. At this stage, Alcama first appears in the center of the cluster  
7 and then gradually spreads to all interfaces among cluster cells. Then as these cells  
8 emigrate from the cluster, they do so as strings of cells still enriched in Alcama at their  
9 interfaces. Suppression of Alcama function reduced the number of emigrating SCPs,  
10 their contacts among each other, and their migratory capacity. The latter defect  
11 correlated with a less efficient polarization of the cell and its F-actin dynamics relative  
12 to the ventral-wards direction of migration. The augmented filopodial dynamics  
13 observed in Alcama- $\Delta$ N expressing SCPs may be favored by the lack of Alcama-  
14 mediated cell-cell contacts, while the still present short cytoplasmic domain of this  
15 overexpressed Alcama- $\Delta$ N form may trigger more F-actin dynamics generating  
16 filopodia. Conversely, VC cells overexpressing a mutant Alcama form in which the  
17 cytoplasmic domain is no longer able to bind PDZ domain containing actin-binding  
18 proteins such as syntenin-1<sup>22,23,24</sup> showed a lack of filopodial dynamics, more extended  
19 cell-cell contacts, and an even more complete lack of apparent cell polarity.

20       Suppression of Pdgfr- $\alpha$  function affected the emergence and ventral-wards  
21 migration of sclerotome derivatives at least as strongly as Alcama deficiency. Our  
22 finding that both Alcama and Pdgfr- $\alpha$  deficiencies led to a strong decrease in pERK  
23 signaling in the ventro-caudal region suggests that the intracellular signaling pathways  
24 downstream of Alcama and Pdgfr- $\alpha$  overlap within the stromal derivatives of the  
25 sclerotome. In addition, we found PI3K activation to be an obligatory step downstream  
26 of Pdgfr- $\alpha$  activation for the development of these cells. Interestingly, the dorsal-wards  
27 migration of sclerotome cells was also affected in embryos treated with a PI3K $\alpha,\gamma$   
28 inhibitor, indicating that even though distinct pathways are likely involved in the dorsal  
29 and ventral migrations of sclerotome derivatives, both use PI3K as a necessary  
30 downstream effector (Fig. S6).

31       Clements & Traver<sup>44</sup> suggested that cells derived from the trunk sclerotome  
32 were required for the emergence of HSPCs. Nguyen et al.<sup>45</sup> then found that somite-  
33 derived pax3a:eGFP<sup>+</sup> cells fostered HSPC emergence, but interpreted them as



1 dermomyotome-derived cells integrating into the DA endothelium. Here we have  
2 confirmed their finding but clarified that these *pax3a:eGFP<sup>+</sup>* cells are actually  
3 sclerotome-derived, DA-associated mesenchymal cells. At least some of them, lateral  
4 and ventral to the aorta, are most likely precursors of the mural cells later ensheathing  
5 the DA that were shown to arise from trunk somites<sup>46,47</sup> – more precisely the  
6 sclerotome, as in mammals and birds<sup>48,49</sup>, and to initially associate with the aorta floor.  
7 Those seen in close association with the dorsal wall of the axial vein (PCV) underlying  
8 the aorta are highly reminiscent of the stromal cells that we previously found by  
9 electron microscopy bridging gaps between adjacent venous endothelial cells at this  
10 very location<sup>6</sup>, which is where aorta-derived HSPCs enter circulation in zebrafish.  
11 Altogether our present study leads to the unifying conclusion that the somitic VCs  
12 identified as the sclerotome successively give rise to mesenchymal cells involved in  
13 the first two main stages of HSPC development and function. Trunk somites first  
14 contribute mesenchymal stromal cells that foster the emergence of HSPCs from the  
15 neighboring DA floor, then the later formed caudal somites contribute mesenchymal  
16 stromal cells that are key components of the first niche where the aorta-derived HSPCs  
17 settle, expand and undergo multi-lineage differentiation.

18 Our study further revealed that *Alcama* and *Pdgfr- $\alpha$* , known as mere markers of  
19 MSCs in mammals, are actually instrumental for the very emergence and emigration  
20 of mesenchymal stromal cells from the somites to build the hematopoietic niches both  
21 in the trunk and tail. Our new *Tg(cspg4:Gal4)* line, which highlights mesenchymal  
22 stromal cells from their sclerotomal origin onwards, will be a precious tool to discern,  
23 notably through single-cell transcriptome analysis, whether cellular heterogeneities  
24 prefiguring different fates are already present within the somitic VCs, and how different  
25 the stromal cells fostering HSPC emergence from the aorta are from those that then  
26 nurture HSPC expansion and multi-lineage differentiation in the CHT niche. Finally,  
27 beyond stem/stromal cells found in hematopoietic organs, cells with MSC capacities  
28 have been extracted from a variety of fetal and adult mammalian tissues, but their  
29 precise origin within these tissues has remained elusive. Crisan et al.<sup>50</sup> presented data  
30 suggesting that these various tissue MSCs were perivascular mesenchymal  
31 cells/pericytes. Interestingly, *cspg4* expression, which we found here to mark the early  
32 sclerotome and its derived cells, is a typical marker of pericytes<sup>51,52</sup>. Therefore  
33 altogether our study makes it reasonable to anticipate that developmentally, MSCs  
34 from most if not all tissues posterior to the head will prove to arise from the sclerotome.

- 1 Elucidation of the molecular mechanisms of MSC development will contribute to the
- 2 field of regenerative medicine by facilitating the induction and manipulation of rare
- 3 MSC populations in adult tissues.

## 1 **Materials and Methods**

2

### 3 **Zebrafish**

4 Fish were maintained in our zebrafish facility at Institut Pasteur. Embryos were  
5 obtained through natural crosses, raised at 28°C in embryo water [Volvic® water  
6 containing 0.28 mg/ml Methylene Blue (M-4159; Sigma) and 0.03mg/ml 1-phenyl-2-  
7 thiourea (P-7629; Sigma)], and staged according to Kimmel et al.<sup>53</sup> For this study, we  
8 used the previously described transgenic lines *Tg(ET37:GFP)*<sup>54</sup>, *Tg(pax3a:EGFP)*<sup>il150,</sup>  
9 <sup>55</sup>, *Tg(UAS:Lifeact-GFP)*<sup>mu271, 32</sup>, *Tg(7xTCF-Xla.Siam:nlsmCherry)*<sup>56</sup>, *Tg(kdrl:ras-*  
10 *mCherry)*<sup>57</sup> and *Tg(lmo2:DsRed)*<sup>58</sup>.

11

### 12 **BAC recombineering and transgenesis**

13 The tol2 and BAC recombineering vectors were kindly provided by K. Kawakami  
14 (National Institute of Genetics, Mishima). A BAC DNA containing the *cspg4* gene  
15 (DKEY-105I23) was purchased from Source BioScience. The *TgBAC(cspg4:GAL4)*  
16 line was firstly generated by recombining a iTol2-amp cassette to the BAC vector<sup>59</sup>,  
17 then a second recombineering was performed targeting a cassette containing GAL4  
18 (pGAL4FF-FRT-Kan-FRT) flanked by 50 bp arms homologous to the region around  
19 the translation start of the *cspg4* gene. Primers used for the 1st and 2nd  
20 recombineering steps are listed in the Supplementary information (Table 1).  
21 Recombination was performed using RedET methodology (K001, GeneBridges) as  
22 described in a previous report<sup>60</sup>. BAC DNAs were prepared using NucleoBond BAC  
23 100 (740579, Marchery-Nagel). *Tg(UAS:RFP)* embryos were injected with 1 nl of mix  
24 solution of 100 ng/μl BAC DNA and 50 ng/μl Tol2 mRNA at 1-cell stage.

25

### 26 **In situ hybridization, immunostaining and TUNEL**

27 Whole-mount RNA *in situ* hybridization (WISH) was performed according to  
28 Thisse [\(<https://wiki.zfin.org/display/prot/Thisse+Lab+-+In+Situ+Hybridization+Protocol+-+2010+update>\)](https://wiki.zfin.org/display/prot/Thisse+Lab+-+In+Situ+Hybridization+Protocol+-+2010+update). Riboprobes were synthesized from  
29 PCR fragments amplified from cDNA extracted and synthesized from the tails of wild-  
30 type embryos as a template, or by reverse transcription of linearized plasmids. The  
31 probes used in this study are indicated in the Supplementary information (Table 2a,2b).

32 Whole-mount fluorescent immunostaining was carried out as described<sup>5</sup>. The  
33 list of primary and secondary antibodies and concentrations used is shown in the  
34

1 Supplementary material (Table 3). TUNEL staining was performed using ApopTag Red  
2 In Situ Apoptosis Detection Kit (S7100, MerckMillipore) combined with peroxidase  
3 (POD) coupled anti-DIG antibody (1/200, #11207733910, Roche) followed by  
4 tyramide-based amplification<sup>61</sup>.

5

## 6 **Construction of mutant form of *alcama* and *pdgfra***

7 *UAS:alcama-ΔN-eGFP*, *UAS:alcama-ΔPDZ-eGFP* and *UAS:alcama-FL-eGFP*

8 Firstly, the *alcama* ORF was cloned to utilize as a template for the following  
9 PCRs (details of cloning are indicated below). For *alcama-ΔN* construct, a DNA  
10 fragment missing to encode amino acids 25-238 corresponding to the two amino-  
11 terminal Ig-like domains of Alcama was amplified. For the *alcama-ΔPDZ* construct, 3  
12 amino acid substitutions were introduced in a putative PDZ domain binding motif at  
13 positions 533-539 (KTRQGSW->**MVRQGSG**) by site-directed mutagenesis. Primers  
14 used for the mutagenesis are listed in Supplementary information (Table 4). Control  
15 *alcama-FL* (full length) and mutated *alcama* fragments were cloned into the Nco I site  
16 of UAS:eGFP vector in frame with eGFP using Gibson assembly (#E5510, NEB).

17

18 *hsp70:pdgfra-ΔPI3K-HA* and *hsp70:pdgfra-FL-HA*

19 A zebrafish *pdgfra-ΔPI3K* was designed based precisely on the human  
20 dominant-negative *pdgfra*, with the substitutions of Y706F (Y731F in human) and  
21 Y717F (Y742F)<sup>25</sup>. Fragments containing amino acid substitutions were amplified by  
22 PCR using the clone containing full-length wt *pdgfra* (kindly provided by J. Eberhart,  
23 University of Texas at Austin) as a template. A 3 kb fragment covering the ORF was  
24 amplified in three fragments and the point-mutations were introduced to the  
25 appropriate fragments using primers listed in Supplementary information (Table 4). A  
26 tandem HA-tag sequence was added in frame at a C-terminal of *pdgfra*. Fragments  
27 encoding control or mutant *pdgfra* were cloned into *hsp70* vector using Gibson  
28 assembly.

29

## 30 **Transient transgenesis**

31 Plasmid DNA for each construct was co-injected with capped mRNA coding for  
32 the Tol2 transposase into 1-cell stage embryos at a concentration of 250 and 25 ng/μl,  
33 respectively.

1

## 2 **RNA/cDNA synthesis, plasmid construction and injection**

3 Total RNA was extracted with the TRIzol reagent (15596026, Invitrogen) from  
4 tails of anesthetized embryos at 23 hpf. Tail total RNA was reverse transcribed into  
5 cDNA using a Superscript IV reverse transcriptase (18091050, Invitrogen). For *alcama*,  
6 *pdgfaa*, *pdgfab*, *pdgfb* and *twist1b*, ORFs were amplified by PCR using tail cDNA as  
7 a template for the subcloning into the TOPO vector and then reinserted into pExpress1  
8 vector using Gibson assembly. ORFs of *pax9* and *snai2* were amplified by PCR from  
9 tail cDNA then cloned directly into pExpress1 vector. Primers used for the cloning are  
10 listed in Supplementary information (Table 5). mRNAs were synthesized using  
11 mMessage mMachine transcription kit (AM1344, Ambion). Capped mRNAs were  
12 injected into 1-cell-stage embryos at the amount of 100 pg.

13

## 14 **Morpholinos and qPCR**

15 Morpholino oligonucleotides (Gene Tools) were injected (0.5-1 nl) into 1-cell-  
16 stage embryo at the amount specified; *alcama* MO<sup>14</sup> (2 ng), *pdgfra* MO<sup>36</sup> (4 ng), *pax9*  
17 MO<sup>62,63</sup> (6 ng), *snai2* MO<sup>63,64</sup> (8 ng) and *twist1a* and *twist1b* MOs<sup>65</sup> (2 ng each). MO  
18 sequences are shown in the Supplementary information (Table 6). For quantitative  
19 real-time PCR (qPCR), total RNA were extracted from 3 independent groups of 40 tails  
20 dissected from embryos at 23 hpf to synthesize template cDNAs. The primers used for  
21 qPCR are shown in the Supplementary information (Table 7). All qPCR experiments  
22 were performed with measurements taken from 3 technical replicates. Fold changes  
23 in gene expression were calculated using the  $2^{-\Delta\Delta CT}$  method and normalized to *ef1a*.

24

## 25 **Heat-shock treatment**

26 Embryos were heat-shocked by placing them in pre-warmed Volvic water for 30  
27 min at 39°C then transferred to 28°C until in vivo observation<sup>38</sup>.

28

## 29 **Promoter cloning and Dual-Luciferase assay**

30 3.3 and 3.2 kb promoter regions of *alcama* and *pdgfra* genes were cloned from  
31 BAC DNA (*alcama*: RP71-78P1, BACPAC Resources; *pdgfra*: DKEY-97C6, Source  
32 BioScience) and cloned into the pGL3 basic vector (E1751, Promega) linearized with  
33 Xho I and Hind III (pGL-*alcama*-luc and pGL-*pdgfra*-luc). Primers used for promoter  
34 cloning are listed in Supplementary information (Table 8). To assess *alcama* and

1 *pdgfra* promoter activities in response to various TFs, WT embryos were injected at  
2 the 1-cell stage with luciferase vectors (pGL-alcama-luc or pGL-pdgfra-luc), control  
3 (Renilla) expression vector (pRL-TK; E2241, Promega), and specified amount of  
4 Morpholino or appropriate mRNA encoding TF (co-injection condition is listed in  
5 Supplementary information; Table 9). Tails were dissected from the injected embryos  
6 at 23-24 hpf and lysed with passive lysis buffer (E1941, Promega) for subsequent  
7 Dual-Luciferase assay following the manufacturer's instructions (E1910, Promega).

8

## 9 **Drug treatments**

10 Pharmacological inhibitors were all solubilized in DMSO (Sigma) and  
11 appropriate DMSO controls (0.2 %) were used for all experiments. Embryos treated  
12 with AS605240 (2  $\mu$ M; S1410, Selleckchem), LY294002 (20  $\mu$ M; S1105, Selleckchem)  
13 and CAL101 (10  $\mu$ M; S2226, Selleckchem) from 19-20 hpf embryos then live-images  
14 were taken with drugs in agarose and embryo water supplemented with tricaine. For  
15 WISH, embryos were treated with drug from 19-20 hpf until the stage of interest, then  
16 fixed in 4% methanol-free formaldehyde overnight.

17

## 18 **Live imaging, image processing and quantification**

19 VE-DIC (video-enhanced differential interference contrast) microscopy was  
20 performed using a Polyvar2 microscope (Reichert) as described previously<sup>66</sup>. Confocal  
21 fluorescence microscopy was performed on Leica SPE and SP8 set-ups and Andor  
22 spinning disk set-up as described previously<sup>4,7</sup>.

23 The image processing was basically performed using Fiji<sup>67</sup>. Measurements of  
24 surface area and volume on migrating SCPs were performed using IMARIS software  
25 (Bitplane). Cell tracking was performed using Manual tracking plugin (Fiji) and the  
26 obtained data were 1) plotted with a Python script developed by S. Rigaud (Image  
27 Analysis Hub (IAH) of Institut Pasteur) or 2) imported into the Chemotaxis and  
28 Migration Tool plugin<sup>68</sup> (Fiji). For the analysis of filopodial dynamics, Filopodyan  
29 plugin<sup>69</sup> was used on Fiji. First, we obtained time-lapse movies (6 min intervals, 23-38  
30 hpf) of the migrating lifeact-GFP<sup>+</sup> SCPs injected with control or alcama MO (7 leader  
31 cells were analyzed for each condition). We extracted 7-10 timepoints from the time  
32 that the leader cell left its followers and measured the orientation of the filopodia for  
33 each timepoint. The cut-off threshold was set to 3  $\mu$ m.

1 The direction of SCP migration was obtained from the positional information at the first  
2 and last timepoints. The angle of filopodia relative to the direction of SCP migration  
3 was calculated with a Python script developed by D. Ershov (IAH, Institut Pasteur).

#### 4 5 **Statistical analysis and replication**

6 Statistical analysis was performed using GraphPad Prism 9. For data that  
7 followed a normal distribution, statistical significance was assessed by a two-tailed  
8 Student's *t*-test, while Mann-Whitney test was introduced for two groups with unequal  
9 variances. Significance levels were set at \* $p < 0.05$ , \*\* $p < 0.005$ , \*\*\* $p < 0.0005$  and  
10 \*\*\*\* $p < 0.0001$ . Data are shown as mean or median $\pm$ SD. All experiments are a  
11 representation of at least three independent experiments unless stated otherwise. For  
12 qPCR and luciferase assays, results were collected with three biological replicates.

#### 13 14 15 **Acknowledgements**

16 We thank our fish facility team for zebrafish care, K. Kawakami (National  
17 Institute of Genetics, Mishima) for providing us with the BAC recombineering plasmids,  
18 J. Eberhart (University of Texas at Austin) for the pdgfra:pCR4 plasmid, B. Appel  
19 (University of Colorado) for the cspg4:pJC53.2 plasmid, and A. Kudo (Tokyo Institute  
20 of Technology, Nagatsuta) for the pax9:pPICT3 plasmid. We also thank Stephane  
21 Rigaud, Dmitry Ershov and Jean-Yves Tinevez (IAH of Institut Pasteur) for  
22 implementation of Python scripts for filopodia analysis. We gratefully acknowledge K.  
23 McElreavey, D. Houzelstein and C. Eozenou (Institut Pasteur) for their help with  
24 Luciferase assays. We are also thankful to N. Wolff and M. Genera (Institut Pasteur)  
25 for their help with Western blotting.

#### 26 27 **Author contributions**

28 E.M. conceived the project, designed, performed, and analyzed experiments, and  
29 wrote the manuscript. C.V. conducted experiments and fish care. A.S. subcloned the  
30 hsp70 vector and assisted with helpful discussions. A-L.T. conducted experiments. P.H.  
31 analyzed, discussed, and suggested experiments, and wrote the manuscript.

#### 32 33 **Competing interests**

34 The authors declare no competing interests.

1

2 **Funding**

3 This work was supported by Institut Pasteur, CNRS, and by grants to P.H. from the  
4 Fondation pour la Recherche Médicale (#DEQ20160334881), the Fondation ARC pour  
5 la Recherche sur le Cancer, and the Agence Nationale de la Recherche Laboratoire  
6 d'Excellence Revive (Investissement d'Avenir; ANR-10-LABX-73).


7





1 RFP/GFP double-positive cells in the CHT. Scale bars, 20  $\mu$ m. **C**, WISH for *alcama* at 23 hpf. Arrows  
2 and arrowheads point at somite VCs and cells prefiguring the future horizontal myoseptum, respectively.  
3 A dotted line outlines the somite ventral border. **D**, Immunostaining for *Alcama* (red), *pax3a:eGFP*  
4 (green), together with DAPI (blue) at 23 hpf. **a**, Overlay of the red, blue and green signals; arrows point  
5 at *Alcama* labeling in the somite VCs. **b**, Same image as **a** without DAPI staining. **e**, epidermis. **c**, At a  
6 deeper focal plane, strong *Alcama* signals were detected at contacts between cells migrating semi-  
7 collectively dorsal-wards (arrowheads) and ventral-wards (arrows). Dashed lines delineate the VCs and  
8 somite borders. Scale bars, 20  $\mu$ m. **E**, Confocal maximum projections of control or *alcama* MO injected  
9 *Tg(pax3a:eGFP; TCF:nls-mCherry)* embryos at 25 (**a,b**) and 27.5 (**c,d**) hpf. (**a,b**) Arrowheads show  
10 SCPs in the early stages of migration; magenta and blue asterisks point to the same cells as in panels  
11 **c** and **d**, respectively. (**c,d**) Arrows point at the intercellular junctions of migrating SCPs, which are much  
12 thinner in **d**. Two blue asterisks in **d** indicate that the similarly labelled cell in **b** has undergone mitosis.  
13 Scale bars, 25  $\mu$ m. **F**, Confocal projections of control or *alcama* MO injected *Tg(cspg4:GAL4;*  
14 *UAS:Lifeact-eGFP)* at 26 hpf. Dashed lines indicate the somite ventral borders. Arrows point at the  
15 connections between migrating SCPs. Magnified images are shown in **c** and **d**. Scale bars, 20  $\mu$ m. **G**,  
16 Quantification of ET37:eGFP<sup>+</sup> cells in the ventral tail of live control and *alcama* MO injected embryos,  
17 at 24 and 30 hpf over a 5-somites width (n=8 embryos each; mean $\pm$ SD; \*\*\*\*, P<0.0001. Student's *t*-  
18 test). At 24 hpf, all GFP<sup>+</sup> cells ventral to the notochord were counted; at 30 hpf, all GFP<sup>+</sup> cells ventral to  
19 the somites were counted. **H**, Confocal projections of control or *alcama* MO injected *Tg(ET37:eGFP;*  
20 *cspg4:GAL4; UAS:RFP)* embryos at 46 hpf. Dashed lines delineate the CHT. nc, notochord; CA, caudal  
21 artery; CHT, caudal hematopoietic tissue; CF, caudal fin.

Fig. 2




1

2 **Figure 2. Alcama regulates SCP migration.**

3 **A**, Time-lapse confocal images of a migrating SCP leader cell from control or alcama MO injected  
4 *Tg(cspg4:Gal4; UAS:Lifeact-GFP)* embryos around 28 hpf. The time point from the initiation of SCP  
5 migration is shown in the upper right corner of each panel. The time lag between control and alcama  
6 morphant SCPs is due to the fact that the latter tend to take more time to fully egress from the somite.  
7 Arrow indicates the direction of cell migration. Scale bars, 10 μm. **B**, Violin plot of filopodia angles relative  
8 to the direction of migration for leader SCPs in control and alcama morphant embryos (n=7 SCPs for  
9 each group, from 3 independent experiments; median±SD; \*\*\*\*,  $P < 0.0001$ ; Mann-Whitney test). **C**,  
10 Filopodia length as a function of their relative angles for leader SCPs in control and alcama morphants.  
11 **D**, Overlay of individual tracks of control and alcama-deficient SCPs during their migration towards the  
12 CHT. In a trajectory plot, all (x, y) coordinates of the SCPs' starting points (in the clusters) are set to  
13 (0,0) and negative or positive values on the Y axis indicate ventral-wards or dorsal-wards migration,  
14 respectively.  $n_{Exp}=4$ ,  $n_{embryos}=6$ ,  $n_{tracked\ cells}=19$  and 17 for control or alcama morphants, respectively.  
15 **E**, **a**, Schematic representation of Alcama-FL-eGFP and Alcama-ΔN-eGFP mutant constructs. Pink and  
16 blue ovals indicate the V-type and C2 type Ig-like domains, respectively. The beige rectangle represents

1 the short cytoplasmic domain. Light blue and green hexagons represent the signal peptide and GFP,  
2 respectively. **b**, Appearance of Alcama- $\Delta$ N-eGFP<sup>+</sup> SCPs at 23 hpf. White asterisk indicates the same  
3 cell as shown in **c** and **d**. Dotted lines delineate somite and notochord borders. Scale bar, 20  $\mu$ m. **c**,  
4 Morphological evolution over 15.5 hrs of the Alcama- $\Delta$ N-eGFP<sup>+</sup> SCP shown in **b** (See also Movie 4).  
5 Scale bar, 10  $\mu$ m. **d**, End point of the time-lapse imaging shown in (**b,c**) and Movie 4. GFP<sup>+</sup> SCPs  
6 marked by yellow asterisks did not migrate out of the somites, whereas RFP<sup>+</sup>/GFP<sup>-</sup> WT SCPs showed  
7 a normal emigration pattern exemplified by the three colored trajectories. A straight dotted line indicates  
8 the notochord lower border. **F, a**, Schematic representation of Alcama-FL-eGFP and Alcama- $\Delta$ PDZ-  
9 eGFP mutant constructs. The red X in the beige rectangle indicates the mutated PDZ binding motif in  
10 the cytoplasmic domain. **b**, Appearance at 23 hpf of an Alcama- $\Delta$ PDZ-eGFP expressing VC cell  
11 (asterisk) followed up over time in **c** (see also Movie 5). Scale bar, 20  $\mu$ m. **c**, Arrows point at large  
12 contact areas between the GFP<sup>+</sup> cell and neighboring RFP<sup>+</sup> cells. **d**, End point of the time-lapse imaging  
13 of the same embryo shown in **b**; the GFP<sup>+</sup> SCP followed up in (**b,c**) had disappeared by 42 hpf, while  
14 another such cell displayed short-distance migration (arrowhead). RFP<sup>+</sup>/GFP<sup>-</sup> (WT) SCPs showed a  
15 normal emigration pattern indicated by three colored trajectories. Straight and curvy dashes lines  
16 delineate the ventral border of notochord and somites. **G**, Dorsal-wards migration of Alcama- $\Delta$ N-eGFP  
17 and - $\Delta$ PDZ-eGFP expressing cells (arrows) by 27 hpf. Scale bars, 10  $\mu$ m. Magenta asterisks in **F-d** and  
18 **G-b** label GFP<sup>+</sup> notochord cells. **H**, Overlay of individual tracks of control (RFP<sup>+</sup>/GFP<sup>-</sup> SCPs; orange and  
19 blue lines) and Alcama- $\Delta$ N-eGFP expressing SCPs (black and red lines).  $n_{Exp}=5$ ,  $n_{embryos}=7$ ,  $n_{tracked}$   
20  $cells=29$  and 17 for Alcama- $\Delta$ N-eGFP<sup>+</sup> and control RFP<sup>+</sup>/GFP<sup>-</sup> SCPs, respectively. **I**, Overlay of individual  
21 tracks of control (RFP<sup>+</sup>/GFP<sup>-</sup> SCPs; orange and blue lines) and Alcama- $\Delta$ PDZ-eGFP<sup>+</sup> SCPs (black and  
22 red lines).  $n_{Exp}=4$ ,  $n_{embryos}=5$ ,  $n_{tracked}$   $cells=32$  and 17 for Alcama- $\Delta$ PDZ-eGFP<sup>+</sup> and control SCPs,  
23 respectively. **J**, Frequency histogram of D/V migration patterns of Alcama- $\Delta$ N-eGFP<sup>+</sup> and - $\Delta$ PDZ-eGFP<sup>+</sup>  
24 cells compared with GFP<sup>+</sup> cells of *Tg(cspg4:Gal4;UAS :GFP)* embryos at 38 hpf. The number of  
25 embryos analyzed was 24 (WT), 36 (Alcama- $\Delta$ N) and 44 (Alcama- $\Delta$ PDZ) from three independent  
26 experiments. nc, notochord.  
27


Fig 3



**Figure 3. PDGFR $\alpha$ /PI3K signaling regulates SCP migration.**

**A, a**, Immunofluorescence for pERK at 26 hpf in the tail region of embryos injected with control MO, alcama MO, or alcama MO + alcama mRNA (“rescue”). Representatives of 12 embryos from two independent experiments are shown. Dashed lines indicate the border of CHT. **b**, Quantification of **a** (n=12 embryos for each group; mean $\pm$ SD; \*\*\*\*,  $P < 0.0001$ , Student's *t*-test). **B**, Confocal projections of live control (**a,c,e**) or *pdgfra* (**b,d,f**) MO injected *Tg(ET37:eGFP; TCF:nls-mCherry)* embryos from 23 to 28 hpf. Arrowheads point at cohesion defects observed in the VCs of *pdgfra* MO injected embryos. White and magenta arrows indicate emerging (**c,d**) and migrating (**e,f**) SCPs, respectively. **C**, Quantification of ET37:eGFP<sup>+</sup> stromal cells and FMCs in control and *pdgfra* MO injected embryos at 40 hpf (n=8 for each group, from the same experiment; mean $\pm$ SD; \*\*\*\*,  $P < 0.0001$ , Student's *t*-test). **D**, Confocal projections of control, alcama and *pdgfra* MO injected *Tg(ET37:eGFP; lmo2:DsRed)* embryos at 48 hpf. An enlarged view of the area enclosed by the dashed square is shown in the middle panel, and as an optical transverse section in the right panel. **E**, Quantification of TCF:nmCherry<sup>+</sup> stromal cells in the CHT of control embryos (n=9), or embryos treated from 20 hpf with AS605240 (n=10), LY294002 (n=10), or CAL101 (n=9) at 40 hpf. Mean $\pm$ SD; \*\*\*\*,  $P < 0.0001$ , Student's *t*-test. **F**, WISH for *pdgfra* at 23 and 36 hpf in 0.2 % DMSO (control) and AS605240-treated embryos. Arrows and arrowheads in **a** indicate VC cells migrating towards the notochord and dorsal mesenchymal cells in the control embryo at 23 hpf, respectively. Arrows in **d** show SCPs slightly dispersed around the VCs at 36 hpf. CA, caudal artery; CV, definitive caudal vein; Plx, venous plexus; nc, notochord.


Fig. 4



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

**Figure 4. Pdgfra influences cluster cohesion and the following migration behaviour of SCPs through PI3K binding.** **A. a**, Schematic representation of Pdgfra fused to tandem HA-tag (red) at its C-terminus, and amino acid alignment around the site of mutations in the KI (kinase insert) domain. The light blue hexagon and yellow ovals indicate the signal peptide and Ig-like extracellular domains, respectively; JM, juxtamembrane; TK1, tyrosine kinase domain 1; TK2, tyrosine kinase domain 2; tyrosine residues involved in PI3K binding when phosphorylated that we mutated into phenylalanines are shown in red. **b**, Time course of the experiment; HS, heat-shock. **B.** Confocal projections from live *Tg(hsp70:pdgfra-ΔPI3K; pax3a:eGFP)* embryos showing Type I (**a**) and Type II (**b**) cluster cohesion / emergence defects (see also Fig. S4B). Magenta arrow in **a** indicates SCPs overflow out of the cluster before the initiation of migration. This cell population was dispersed in situ after 5 hours (magenta arrowheads). **b**, Arrows indicate multiple SCPs emerging simultaneously from the cluster. **C.** Representative frames from a confocal time-lapse sequence of individual migrating SCP leader cell in *Tg(cspg4:GAL4; UAS:lifeact-eGFP)* embryos injected with the hsp70:pdgfra-FL (**a**) or hsp70:pdgfra-ΔPI3K (**b**) construct and heat-shocked at 20 hpf. Confocal imaging was performed from 23 hpf. Time is indicated in hrs and min. Scale bar, 25 μm. **D.** Quantification of *Tg(cspg4:GAL4; UAS:lifeact-eGFP<sup>+</sup>)* SCPs migrating dorsal-wards (D) or ventral-wards (V) in Pdgfra-FL (control) and Pdgfra-ΔPI3K expressing embryos at 28 hpf (mean±SD; n=7 embryos for control, n=8 for hsp70:pdgfra-ΔPI3K, from 3 independent experiments. \*\*\*\*, P<0.0001, Student's *t*-test. **E.** Counting of *pax3a:eGFP<sup>+</sup>* SCPs in control and hsp70:pdgfra-ΔPI3K embryos in the CHT at 36 hpf, over a 5-somite width (mean±SD; n=11 for control, n=19 for hsp70:pdgfra-ΔPI3K, from 3 independent experiments. \*\*\*\*, P<0.0001, Student's *t*-test.


Fig. 5



2

3 **Figure 5. *alcama* and *pdgfra* are regulated by sclerotome-associated TFs.** **A**, WISH for *pax9*, *snai2*,  
 4 *twist1a* and *twist1b* at 23 hpf in the tail of WT embryos. Arrows point to expression of these genes in the  
 5 somitic VCs. **B**, **a**, a DNA fragment encompassing the 3.3 kb region upstream of the of *alcama* gene  
 6 transcription start site was inserted upstream of the luciferase (luc) coding region of the pGL3-Basic  
 7 plasmid, to give pGL3-*alcama*-luc. **b**, in situ luciferase assays using pGL3-*alcama*-luc, which was  
 8 injected at the 1-cell stage either alone or together with the indicated mRNA or MO; lysates obtained  
 9 from 10-15 tails at 23 hpf for each condition were subjected to luciferase assay (n=9 for each, as  
 10 biological triplicates from three independent experiments) or *pax9* (n=6 for each). The empty vector  
 11 pGL3-Basic and pGL-*alcama*-luc (n=11 for each) were used as negative and positive controls,  
 12 respectively. **C**, qPCR analysis for *alcama* and *pdgfra* in *pax9* morphants and control (n=9 for each, a  
 13 set of biological triplicates from three independent experiments) at 23 hpf. **D**, qPCR analysis for *twist1a*,  
 14 *twist1b* and *snai2* in *pax9* morphants and control (n=9 for each) at 23 hpf. **E**, **a** a DNA fragment covering  
 15 the 3.2 kb region upstream of the *pdgfra* gene transcription start site was inserted upstream of the  
 16 luciferase (luc) coding region of the pGL3-Basic plasmid, to give pGL3-*pdgfra*-luc. **b**, Same experimental  
 17 scheme as in B-b, following injection of the indicated constructs and Mo or mRNA combinations. **F**,  
 18 qPCR analysis for *alcama* and *pdgfra* (n=6 for each) in *twist1a*/*twist1b* double morphants and control  
 19 (n=9) at 23 hpf. **G**, qPCR analysis for *alcama*, *pdgfra* and *pax9* in *snai2* morphants and control (n=3) at  
 20 23 hpf (mean±SD). **H**, A proposed network for the regulation of TFs acting on *alcama* and *pdgfra* during  
 21 SCP development. Line ending with arrow or bar represent activation or repression, respectively.  
 22

Fig. 6



1

2 **Figure 6. *Alcama* and *Pdgfra* are also involved in stromal cell development in the trunk, which**  
 3 **conditions the development of definitive HSPCs. **A**, a**, rostro-caudal extent of sclerotome TFs and  
 4 ***alcama* and *pdgfra* expression by 24 hpf. **b**, WISH for *alcama*, *pdgfra* and *pax9* at 23-24 hpf. Arrows**  
 5 **point at their expression in the somite VCs/sclerotome in the trunk and tail. Arrowheads point at their**  
 6 **expression in the smaller dorsal sclerotome<sup>31</sup>. **B**, Confocal maximum projection (**a**) and single confocal**



1 sections (**b,c**) of the trunk region of a *Tg(pax3a:eGFP; kdrl:ras-mCherry)* embryo at 36 hpf, with vertical  
2 dashed lines showing the position of the optical transverse sections shown on the right (**a',a'',b',c'**).  
3 Arrowheads point at GFP<sup>+</sup> stromal cells located at the DA/notochord or DA/PCV junction, arrows point  
4 at ISV-associated mesenchymal cells, known to originate from the dorsal-wards migration of ventral  
5 sclerotome cells<sup>31,70</sup>. Scale bar, 20  $\mu$ m. (**C,D**) Confocal sections of the trunk region of *Tg(pax3a:eGFP;*  
6 *Imo2:DsRed)* (**C**) and *Tg(ET37:eGFP; Imo2:DsRed)* (**D**) embryos injected with control (**a**), alcama (**b**),  
7 pdgfra (**c**) or pax9 (**d**) MOs. Dashed lines indicate the position of the corresponding transverse section  
8 shown on the right. Arrows and arrowheads point at stromal cells located at the DA/PCV joint or  
9 somewhat lateral to it, respectively. **e**, Quantification of pax3a:eGFP<sup>+</sup> (**C**) or ET37:eGFP<sup>+</sup> (**D**) cells in the  
10 sub-aortic space of 36 hpf live embryos injected with control, alcama, pdgfra or pax9 MO (mean $\pm$ SD;  
11 n=6 embryos for each group. \*\*\*,  $P \leq 0.001$ ; \*\*,  $P \leq 0.01$ ; Student's *t*-test). Counting was done over a 6-  
12 somites width. **E**, WISH for *myb* at 36 (**a**) and 52 (**b**) hpf in embryos injected with control, alcama, pdgfra  
13 or pax9 MO. Arrows and arrowheads point at myb<sup>+</sup> signals in the trunk (arrows) and tail (arrowheads)  
14 regions, respectively. **F**, Quantification of myb<sup>+</sup> cells at 36 hpf as shown in **E-a** (mean $\pm$ SD; n=6 embryos  
15 for control, 8 for alcama, 21 for pdgfra and 10 for pax9 MO injected embryos. \*\*\*\*,  $P \leq 0.0001$ , Student's  
16 *t*-test). DA or A, dorsal aorta; PCV or V, posterior cardinal vein; ISV, intersomitic vessel; sas, sub-aortic  
17 space.

## 1 References

- 2 1. Kissa, K. & Herbomel, P. Blood stem cells emerge from aortic endothelium by a novel  
3 type of cell transition. *Nature* **464**, 112–115 (2010).
- 4 2. Bertrand, J. Y. *et al.* Haematopoietic stem cells derive directly from aortic  
5 endothelium during development. *Nature* **464**, 108–111 (2010).
- 6 3. Boisset, J. C. *et al.* In vivo imaging of haematopoietic cells emerging from the mouse  
7 aortic endothelium. *Nature* **464**, 116–120 (2010).
- 8 4. Lancino, M. *et al.* Anisotropic organization of circumferential actomyosin  
9 characterizes hematopoietic stem cells emergence in the zebrafish. *Elife* **7**, e37355  
10 (2018).
- 11 5. Murayama, E. *et al.* Tracing Hematopoietic Precursor Migration to Successive  
12 Hematopoietic Organs during Zebrafish Development. *Immunity* **25**, 963–975 (2006).
- 13 6. Kissa, K. *et al.* Live imaging of emerging hematopoietic stem cells and early thymus  
14 colonization. *Blood* **111**, 1147–1156 (2008).
- 15 7. Murayama, E. *et al.* NACA deficiency reveals the crucial role of somite-derived stromal  
16 cells in haematopoietic niche formation. *Nat. Commun.* **6**, 8375 (2015).
- 17 8. Morinkensicki, E. M. & Eisen, J. S. Sclerotome development and peripheral nervous  
18 system segmentation in embryonic zebrafish. *Development* **124**, 159–167 (1997).
- 19 9. Stickney, H. L., Barresi, M. J. F. & Devoto, S. H. Somite development in zebrafish. *Dev.*  
20 *Dyn.* **219**, 287–303 (2000).
- 21 10. Degen, W. G. J. *et al.* MEMD, a new cell adhesion molecule in metastasizing human  
22 melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion  
23 molecule). *Am. J. Pathol.* **152**, 805–813 (1998).
- 24 11. Patel, D. D. *et al.* Identification and characterization of a 100-kD ligand for CD6 on  
25 human thymic epithelial cells. *J. Exp. Med.* **181**, 1563–1568 (1995).
- 26 12. Ferragut, F., Vachetta, V. S., Troncoso, M. F., Rabinovich, G. A. & Elola, M. T.  
27 ALCAM/CD166: A pleiotropic mediator of cell adhesion, stemness and cancer  
28 progression. *Cytokine and Growth Factor Reviews* vol. 61 27–37 (2021).
- 29 13. Bye, C. R., Rytova, V., Alsanie, W. F., Parish, C. L. & Thompson, L. H. Axonal growth of  
30 midbrain dopamine neurons is modulated by the cell adhesion molecule ALCAM  
31 through trans-heterophilic interactions with l1cam, Chl1, and semaphorins. *J.*  
32 *Neurosci.* **39**, 6656–6667 (2019).

- 1 14. Choe, C. P. *et al.* Wnt-Dependent Epithelial Transitions Drive Pharyngeal Pouch  
2 Formation. *Dev. Cell* **24**, 296–309 (2013).
- 3 15. Delgado, V. M. C. *et al.* Modulation of endothelial cell migration and angiogenesis: a  
4 novel function for the “tandem-repeat” lectin galectin-8. *FASEB J.* **25**, 242–254 (2011).
- 5 16. Cizelsky, W., Tata, A., Kuhl, M. & Kuhl, S. J. The Wnt/JNK signaling target gene *alcam* is  
6 required for embryonic kidney development. *Development* **141**, 2064–2074 (2014).
- 7 17. Ohneda, O. *et al.* ALCAM (CD166): Its role in hematopoietic and endothelial  
8 development. *Blood* **98**, 2134–2142 (2001).
- 9 18. Willrodt, A. H. *et al.* Stromal Expression of Activated Leukocyte Cell Adhesion  
10 Molecule Promotes Lung Tumor Growth and Metastasis. *Am. J. Pathol.* **187**, 2558–  
11 2569 (2017).
- 12 19. Arai, F., Ohneda, O., Miyamoto, T., Zhang, X. Q. & Suda, T. Mesenchymal stem cells in  
13 perichondrium express activated leukocyte cell adhesion molecule and participate in  
14 bone marrow formation. *J. Exp. Med.* **195**, 1549–1563 (2002).
- 15 20. Brinkhof, B., Zhang, B., Cui, Z., Ye, H. & Wang, H. ALCAM (CD166) as a gene expression  
16 marker for human mesenchymal stromal cell characterisation. *Gene* **763S**, 100031  
17 (2020).
- 18 21. In ’t Anker, P. S. *et al.* Mesenchymal stem cells in human second-trimester bone  
19 marrow, liver, lung, and spleen exhibit a similar immunophenotype but a  
20 heterogeneous multilineage differentiation potential. *Haematologica* **88**, 845–852  
21 (2003).
- 22 22. Tudor, C. *et al.* Syntenin-1 and Ezrin Proteins Link Activated Leukocyte Cell Adhesion  
23 Molecule to the Actin Cytoskeleton. *J. Biol. Chem.* **289**, 13445–13460 (2014).
- 24 23. te Riet, J. *et al.* Dynamic coupling of ALCAM to the actin cortex strengthens cell  
25 adhesion to CD6. *J. Cell Sci.* **127**, 1595–1606 (2014).
- 26 24. te Riet, J. *et al.* Distinct kinetic and mechanical properties govern ALCAM-mediated  
27 interactions as shown by single-molecule force spectroscopy. *J. Cell Sci.* **120**, 3965–  
28 3976 (2007).
- 29 25. Rosenkranz, S., DeMali, K. A., Gelderloos, J. A., Bazenet, C. & Kazlauskas, A.  
30 Identification of the Receptor-associated Signaling Enzymes That Are Required for  
31 Platelet-derived Growth Factor-AA-dependent Chemotaxis and DNA Synthesis. *J. Biol.*  
32 *Chem.* **274**, 28335–28343 (1999).

- 1 26. Hoch, R. V. & Soriano, P. Roles of PDGF in animal development. *Development* vol. 130  
2 4769–4784 (2003).
- 3 27. Tallquist, M. D. & Soriano, P. Cell autonomous requirement for PDGFR $\alpha$  in populations  
4 of cranial and cardiac neural crest cells. *Development* vol. 130 507–518 (2003).
- 5 28. Morikawa, S. *et al.* Prospective identification, isolation, and systemic transplantation  
6 of multipotent mesenchymal stem cells in murine bone marrow. *J. Exp. Med.* **206**,  
7 2483–2496 (2009).
- 8 29. Naganathan, S. R. & Oates, A. C. Patterning and mechanics of somite boundaries in  
9 zebrafish embryos. *Seminars in Cell and Developmental Biology* vol. 107 170–178  
10 (2020).
- 11 30. Lee, R. T. H., Knapik, E. W., Thiery, J. P. & Carney, T. J. An exclusively mesodermal  
12 origin of fin mesenchyme demonstrates that zebrafish trunk neural crest does not  
13 generate ectomesenchyme. *Dev.* **140**, 2923–2932 (2013).
- 14 31. Ma, R. C., Jacobs, C. T., Sharma, P., Kocha, K. M. & Huang, P. Stereotypic generation of  
15 axial tenocytes from bipartite sclerotome domains in zebrafish. *PLOS Genet.* **14**,  
16 e1007775 (2018).
- 17 32. Helker, C. S. M. *et al.* The zebrafish common cardinal veins develop by a novel  
18 mechanism: Lumen ensheathment. *Dev.* **140**, 2776–2786 (2013).
- 19 33. Van Kempen, L. C. L. T. *et al.* Molecular Basis for the Homophilic Activated Leukocyte  
20 Cell Adhesion Molecule (ALCAM)-ALCAM Interaction. *J. Biol. Chem.* **276**, 25783–25790  
21 (2001).
- 22 34. Singh, J., Sharma, K. & Pillai, P. P. PDGFR inhibition mediated intracellular signalling in  
23 C6 glioma growth and migration: role of ERK and ROCK pathway. *Cytotechnology* **70**,  
24 465–477 (2018).
- 25 35. Ip, C. K. M. *et al.* Neomorphic PDGFRA extracellular domain driver mutations are  
26 resistant to PDGFRA targeted therapies. *Nat. Commun.* **9**, 4583 (2018).
- 27 36. French, C. *et al.* Mutation of FOXC1 and PITX2 induces cerebral small-vessel disease.  
28 *CLIN J.* **124**, 4877–4881 (2014).
- 29 37. Fruman, D. A. *et al.* The PI3K Pathway in Human Disease. *Cell* vol. 170 605–635 (2017).
- 30 38. Pouget, C. *et al.* FGF signalling restricts haematopoietic stem cell specification via  
31 modulation of the BMP pathway. *Nat. Commun.* **5**, 5588 (2014).
- 32 39. Wei, Q. & Frenette, P. S. Niches for Hematopoietic Stem Cells and Their Progeny.

- 1            *Immunity* vol. 48 632–648 (2018).
- 2    40.    Ando, K., Shibata, E., Hans, S., Brand, M. & Kawakami, A. Osteoblast Production by  
3            Reserved Progenitor Cells in Zebrafish Bone Regeneration and Maintenance. *Dev. Cell*  
4            **43**, 643-650.e3 (2017).
- 5    41.    Khan, J. A. *et al.* Fetal liver hematopoietic stem cell niches associate with portal  
6            vessels. *Science (80-. )*. **351**, 176–180 (2016).
- 7    42.    Caplan, A. I. & Bruder, S. P. Mesenchymal stem cells: Building blocks for molecular  
8            medicine in the 21st century. *Trends in Molecular Medicine* vol. 7 259–264 (2001).
- 9    43.    Naganathan, S. R., Popović, M. & Oates, A. C. Somite surface tension buffers imprecise  
10           segment lengths to ensure left-right symmetry. *bioRxiv* 2020.08.14.251645 (2020)  
11           doi:10.1101/2020.08.14.251645.
- 12    44.    Clements, W. K. & Traver, D. Signalling pathways that control vertebrate  
13           haematopoietic stem cell specification. *Nat. Rev. Immunol.* **13**, 336–348 (2013).
- 14    45.    Nguyen, P. D. *et al.* Haematopoietic stem cell induction by somite-derived endothelial  
15           cells controlled by meox1. *Nature* **512**, 314–318 (2014).
- 16    46.    Ando, K. *et al.* Clarification of mural cell coverage of vascular endothelial cells by live  
17           imaging of zebrafish. *Development* **143**, 1328–1339 (2016).
- 18    47.    Stratman, A. N. *et al.* Interactions between mural cells and endothelial cells stabilize  
19           the developing zebrafish dorsal aorta. *Dev.* **144**, 115–127 (2017).
- 20    48.    Majesky, M. W. Developmental basis of vascular smooth muscle diversity.  
21           *Arteriosclerosis, Thrombosis, and Vascular Biology* vol. 27 1248–1258 (2007).
- 22    49.    Pouget, C., Pottin, K. & Jaffredo, T. Sclerotomal origin of vascular smooth muscle cells  
23           and pericytes in the embryo. *Dev. Biol.* **315**, 437–447 (2008).
- 24    50.    Crisan, M. *et al.* A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human  
25           Organs. *Cell Stem Cell* **3**, 301–313 (2008).
- 26    51.    Birbrair, A. *et al.* Skeletal muscle pericyte subtypes differ in their differentiation  
27           potential. *Stem Cell Res.* **10**, 67–84 (2013).
- 28    52.    Kunisaki, Y. *et al.* Arteriolar niches maintain haematopoietic stem cell quiescence.  
29           *Nature* **502**, 637–643 (2013).
- 30    53.    Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of  
31           embryonic development of the zebrafish. *Dev. Dyn.* **203**, 253–310 (1995).
- 32    54.    Parinov, S., Kondrichin, I., Korzh, V. & Emelyanov, A. Tol2 transposon-mediated

- 1 enhancer trap to identify developmentally regulated zebrafish genes in vivo. *Dev. Dyn.*  
2 **231**, 449–459 (2004).
- 3 55. Seger, C. *et al.* Analysis of Pax7 expressing myogenic cells in zebrafish muscle  
4 development, injury, and models of disease. *Dev. Dyn.* **240**, 2440–2451 (2011).
- 5 56. Moro, E. *et al.* In vivo Wnt signaling tracing through a transgenic biosensor fish reveals  
6 novel activity domains. *Dev. Biol.* **366**, 327–340 (2012).
- 7 57. Chi, N. C. *et al.* Foxn4 directly regulates tbx2b expression and atrioventricular canal  
8 formation. *Genes Dev.* **22**, 734–739 (2008).
- 9 58. Zhu, H. *et al.* Regulation of the lmo2 promoter during hematopoietic and vascular  
10 development in zebrafish. *Dev. Biol.* **281**, 256–269 (2005).
- 11 59. Suster, M. L., Abe, G., Schouw, A. & Kawakami, K. Transposon-mediated BAC  
12 transgenesis in zebrafish. *Nat. Protoc.* **6**, 1998–2021 (2011).
- 13 60. Bussmann, J. & Schulte-Merker, S. Rapid BAC selection for tol2 -mediated transgenesis  
14 in zebrafish. *Development* **138**, 4327–4332 (2011).
- 15 61. Le Guyader, D. *et al.* Origins and unconventional behavior of neutrophils in developing  
16 zebrafish. *Blood* **111**, 132–141 (2008).
- 17 62. Swartz, M. E., Sheehan-Rooney, K., Dixon, M. J. & Eberhart, J. K. Examination of a  
18 palatogenic gene program in zebrafish. *Dev. Dyn.* **240**, 2204–2220 (2011).
- 19 63. Charbord, P. *et al.* A Systems Biology Approach for Defining the Molecular Framework  
20 of the Hematopoietic Stem Cell Niche. *Cell Stem Cell* **15**, 376–391 (2014).
- 21 64. Bickers, C., Españaola, S. D., Grainger, S., Pouget, C. & Traver, D. Zebrafish snai2  
22 mutants fail to phenocopy morphant phenotypes. *PLoS One* **13**, e0202747 (2018).
- 23 65. Das, A. & Crump, J. G. Bmps and Id2a Act Upstream of Twist1 To Restrict  
24 Ectomesenchyme Potential of the Cranial Neural Crest. *PLoS Genet.* **8**, e1002710  
25 (2012).
- 26 66. Herbomel, P. & Levraud, J. P. Imaging early macrophage differentiation, migration,  
27 and behaviors in live zebrafish embryos. *Methods in molecular medicine* vol. 105 199–  
28 214 (2005).
- 29 67. Schindelin, J. *et al.* Fiji: An open-source platform for biological-image analysis. *Nature*  
30 *Methods* vol. 9 676–682 (2012).
- 31 68. Zengel, P. *et al.*  $\mu$ -Slide Chemotaxis: A new chamber for long-term chemotaxis studies.  
32 *BMC Cell Biol.* **12**, 21 (2011).

- 1 69. Urbancic, V. *et al.* Filopodyan: An open-source pipeline for the analysis of filopodia. *J.*  
2 *Cell Biol.* **216**, 3405–3422 (2017).
- 3 70. Rajan, A. M., Ma, R. C., Kocha, K. M., Zhang, D. J. & Huang, P. Dual function of  
4 perivascular fibroblasts in vascular stabilization in zebrafish. *PLOS Genet.* **16**,  
5 e1008800 (2020).
- 6

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Movie5.mp4](#)
- [SupplInfoMurayama2022NC.pdf](#)
- [Movie7.mp4](#)
- [Movie2.mp4](#)
- [Movie4.mp4](#)
- [Movie8.mp4](#)
- [Movie3.mp4](#)
- [Movie1.mp4](#)
- [Movie6.mp4](#)